138 related articles for article (PubMed ID: 10792183)
1. Effects of finasteride and bicalutamide on prostatic blood flow in the rat.
Lekås E; Bergh A; Damber JE
BJU Int; 2000 May; 85(7):962-5. PubMed ID: 10792183
[TBL] [Abstract][Full Text] [Related]
2. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study.
Kaya C; Ozyurek M; Turkeri LN
Int J Urol; 2005 Feb; 12(2):194-8. PubMed ID: 15733115
[TBL] [Abstract][Full Text] [Related]
3. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
Shibata Y; Ono Y; Kashiwagi B; Suzuki K; Fukabori Y; Honma S; Yamanaka H
Urology; 2003 Nov; 62(5):942-6. PubMed ID: 14624931
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Cancer Chemother Pharmacol; 2000; 45(1):31-7. PubMed ID: 10647498
[TBL] [Abstract][Full Text] [Related]
5. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex.
Tsukamoto S; Akaza H; Imada S; Koiso K; Shirai T; Ideyama Y; Kudo M
J Natl Cancer Inst; 1995 Jun; 87(11):842-3. PubMed ID: 7791234
[No Abstract] [Full Text] [Related]
7. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
8. Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormone-releasing hormone analog), Finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate.
Yamashita A; Hayashi N; Sugimura Y; Cunha GR; Kawamura J
Prostate; 1996 Jul; 29(1):1-14. PubMed ID: 8685049
[TBL] [Abstract][Full Text] [Related]
9. Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model.
Yamauchi A; Kawai K; Tsukamoto S; Ideyama Y; Shirai T; Akaza H
J Urol; 2006 Jan; 175(1):348-52. PubMed ID: 16406940
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
11. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
12. Finasteride for prostatic disease: an updated and comprehensive review.
De Nunzio C; Miano R; Trucchi A; Finazzi Agrò E; Tubaro A
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1561-8. PubMed ID: 19040331
[TBL] [Abstract][Full Text] [Related]
13. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Wang LG; Mencher SK; McCarron JP; Ferrari AC
Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
[TBL] [Abstract][Full Text] [Related]
14. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
16. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
17. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.
Tsukamoto S; Akaza H; Onozawa M; Shirai T; Ideyama Y
Cancer; 1998 Feb; 82(3):531-7. PubMed ID: 9452271
[TBL] [Abstract][Full Text] [Related]
18. Biochemical recurrence of prostate cancer.
Moul JW
Curr Probl Cancer; 2003; 27(5):243-72. PubMed ID: 12963877
[No Abstract] [Full Text] [Related]
19. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
20. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
